Parallel Advisors, LLC Arvinas, Inc. Transaction History

Parallel Advisors, LLC

  • $4.18 Billion
  • Q3 2024

A detailed history of Parallel Advisors, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 70 shares of ARVN stock, worth $1,335. This represents 0.0% of its overall portfolio holdings.

Number of Shares
70
Previous 70 -0.0%
Holding current value
$1,335
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
SELL
$14.19 - $42.33 $156 - $465
-11 Reduced 13.58%
70 $2,000
Q3 2023

May 20, 2024
BUY
$19.64 - $28.21 $58 - $84
3 Added 3.85%
81 $1,000
Q3 2023

Nov 13, 2023
BUY
$19.64 - $28.21 $1,590 - $2,285
81 New
81 $1,000
Q1 2023

May 20, 2024
BUY
$26.15 - $37.26 $209 - $298
8 Added 11.43%
78 $2,000
Q1 2023

Apr 25, 2023
BUY
$26.15 - $37.26 $2,039 - $2,906
78 New
78 $2,000
Q4 2022

Feb 03, 2023
BUY
$32.47 - $57.24 $0 - $0
0 New
0 $0
Q2 2022

Aug 01, 2022
SELL
$36.01 - $74.24 $648 - $1,336
-18 Closed
0 $0
Q1 2022

Apr 28, 2022
BUY
$60.27 - $81.57 $1,084 - $1,468
18 New
18 $1,000
Q4 2021

Jan 20, 2022
SELL
$65.85 - $96.21 $5,728 - $8,370
-87 Closed
0 $0
Q3 2021

Nov 02, 2021
BUY
$73.2 - $107.87 $5,124 - $7,550
70 Added 411.76%
87 $7,000
Q1 2021

Apr 23, 2021
BUY
$58.19 - $91.37 $989 - $1,553
17 New
17 $1,000
Q4 2020

Feb 02, 2021
SELL
$20.19 - $84.93 $3,371 - $14,183
-167 Closed
0 $0
Q1 2020

Apr 27, 2020
SELL
$33.0 - $54.5 $825 - $1,362
-25 Reduced 13.02%
167 $6,000
Q4 2019

Jan 30, 2020
BUY
$15.39 - $44.38 $2,954 - $8,520
192 New
192 $8,000

Others Institutions Holding ARVN

# of Institutions
229
Shares Held
68.4M
Call Options Held
226K
Put Options Held
285K
View Full List

About ARVINAS, INC.

ARVN Quotes by TradingView
  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email